Contract102 Capital Gains Option Agreement • March 30th, 2018 • Eloxx Pharmaceuticals, Inc. • Services-commercial physical & biological research • Tel-Aviv
Contract Type FiledMarch 30th, 2018 Company Industry JurisdictionTHIS 102 CAPITAL GAINS OPTION AGREEMENT (this “Agreement”) is made and entered into as of February , 2018, by and between Eloxx Pharmaceuticals Inc., a Corporation registered under the laws of the State of Delaware (the “Corporation”) and [ ] (the “Grantee”) (the Corporation and the Grantee shall sometimes be referred to, each as a “Party” and collectively, as the “Parties”).